NCT03620149 - Reduced Dose-density of Denosumab for Unresectable GCTB | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 26, 2019

Primary Completion Date

July 30, 2020

Study Completion Date

July 30, 2020

Conditions

Bone Giant Cell Tumor

Interventions

DRUG

Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]

Denosumab 120 mg, SC, on day 1 of every 12-week cycle

Trial Locations (8)

Leiden University Medical Centre, Leiden

Hospital Universitario San Carlos, Madrid

IRCCS Istituto Ortopedico Rizzoli, Bologna

Vall d'Hebron Institut d'Oncologia, Barcelona

University College London Hospitals NHS Foundation Trust - University College Hospital, London

Hospital De La Santa Creu I Sant Pau, Barcelona

Institut Catala d'Oncologia - ICO L'Hospitalet - Hospital Duran i Reynals (Institut Catala D'Oncologia), Barcelona

Oxford University Hospitals NHS Trust - Churchill Hospital, Oxford